A robust approach to enhance tumor-selective accumulation of nanoparticles

Oncotarget

Volumn 2, Issue 1-2, 2011, Pages 59-68

  Qiao, Yuan ^a   Huang, Xin ^a   Nimmagadda, Sridhar ^b   Bai, Renyuan ^b   Staedtke, Verena ^b   Foss, Catherine A ^b   Cheong, Ian ^a   Holdhoff, Matthias ^a   Kato, Yoshinori ^b   Pomper, Martin G ^b   Riggins, Gregory J ^b   Kinzler, Kenneth W ^a   Diaz Jr , Luis A ^a   Vogelstein, Bert ^a   Zhou, Shibin ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Inflammation; Nanoparticle; Tnf ; Tumor; Vasculature

Indexed keywords

DOXORUBICIN; NANOPARTICLE; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; ANTINEOPLASTIC AGENT; DRUG CARRIER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL INFECTION; CANCER SURVIVAL; COLORECTAL CARCINOMA; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG RETENTION; DRUG TARGETING; FEMALE; ISOTOPE LABELING; MOUSE; NONHUMAN; RADIOACTIVITY; ANIMAL; CHEMISTRY; DISEASE MODEL; HUMAN; METABOLISM; NEOPLASM; VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; DISEASE MODELS, ANIMAL; DRUG CARRIERS; HUMANS; MICE; NANOPARTICLES; NEOPLASMS;

EID: 79960876539     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.227     Document Type: Article

References (33)

1. Cotran RS, Inflammation, historical perspectives. In, Inflammation, basic principles and clinical correlates. Edited by Gallin JI, Snyderman, R., 3th edn. Philadelphia, Lippincott Williams & Wilkins 1999, 5-10.
2. Dvorak HF, Tumors, wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986, 315(26):1650-1659.
3. Jain RK, Duda DG, Vascular and Interstitial Biology ofTumors. In, ABELOFF'S CLINICAL ONCOLOGY. Edited by Abeloff MD, Armitage JO, Niederhuber JE, Kastan MB, McKenna WG, vol. 1, 4th edn. Philadelphia, Churchill Livingstone Elsevier; 2008, 105-124.
4. Ferrara N, Hillan KJ, Gerber HP, Novotny W, Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004, 3(5):391-400.
5. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E et al, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350(23):2335-2342.
6. Matsumura Y, Maeda H, A new concept for macromolecular therapeutics in cancer chemotherapy, mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986, 46(12 Pt 1):6387-6392.
7. Maeda H, Fang J, Inutsuka T, Kitamoto Y, Vascular permeability enhancement in solid tumor, various factors, mechanisms involved and its implications. Int Immunopharmacol 2003, 3(3):319-328.
8. Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D, Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 1999, 51(4):691-743.
9. Torchilin VP, Micellar nanocarriers, pharmaceutical perspectives. Pharm Res 2007, 24(1):1-16.
10. Maeda H, Bharate GY, Daruwalla J, Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur J Pharm Biopharm 2009, 71(3):409-419.
11. Dang LH, Bettegowda C, Huso DL, Kinzler KW, Vogelstein B, Combination bacteriolytic therapy for the treatment of experimental tumors. Proc Natl Acad Sci U S A 2001, 27:27.
12. Cheong I, Huang X, Bettegowda C, Diaz LA, Jr., Kinzler KW, Zhou S, Vogelstein B, A bacterial protein enhances the release and efficacy of liposomal cancer drugs. Science 2006, 314(5803):1308-1311.
13. Bettegowda C, Huang X, Lin J, Cheong I, Kohli M, Szabo SA, Zhang X, Diaz LA, Jr., Velculescu VE, Parmigiani G et al, The genome and transcriptomes of the anti-tumor agent Clostridium novyi-NT. Nat Biotechnol 2006, 24(12):1573-1580.
14. Coiffier B, Rituximab therapy in malignant lymphoma. Oncogene 2007, 26(25):3603-3613.
15. Jaglowski SM, Byrd JC, Rituximab in chronic lymphocytic leukemia. Semin Hematol, 47(2):156-169.
16. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B, An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A 1975, 72(9):3666-3670.
17. Brett J, Gerlach H, Nawroth P, Steinberg S, Godman G, Stern D, Tumor necrosis factor/cachectin increases permeability of endothelial cell monolayers by a mechanism involvingregulatory G proteins. J Exp Med 1989, 169(6):1977-1991.
18. Mougin-Degraef M, Jestin E, Bruel D, Remaud-Le Saec P, Morandeau L, Faivre-Chauvet A, Barbet J, High-activity radio-iodine labeling of conventional and stealth liposomes. J Liposome Res 2006, 16(1):91-102.
19. Bolton AE, Hunter WM, The labelling of proteins to high specific radioactivities by conjugation to a 125I-containing acylating agent. Biochem J 1973, 133(3):529-539.
20. Plomp M, McCaffery JM, Cheong I, Huang X, Bettegowda C, Kinzler KW, Zhou S, Vogelstein B, Malkin AJ, Spore coat architecture of Clostridium novyi NT spores. J Bacteriol 2007, 189(17):6457-6468.
21. Schwartz EL, Antivascular actions of microtubule-binding drugs. Clin Cancer Res 2009, 15(8):2594-2601.
22. Tozer GM, Kanthou C, Parkins CS, Hill SA, The biology of the combretastatins as tumour vascular targeting agents. Int J Exp Pathol 2002, 83(1):21-38.
23. Holwell SE, Hill BT, Bibby MC, Anti-vascular effects of vinflunine in the MAC 15A transplantable adenocarcinoma model. Br J Cancer 2001, 84(2):290-295.
24. Schiller JH, Storer BE, Witt PL, Alberti D, Tombes MB, Arzoomanian R, Proctor RA, McCarthy D, Brown RR, Voss SD et al, Biological and clinical effects of intravenous tumor necrosis factor-alpha administered three times weekly. Cancer Res 1991, 51(6):1651-1658.
25. Ausman JI, Shapiro WR, Rall DP, Studies on the chemotherapy of experimental brain tumors, development of an experimental model. Cancer Res 1970, 30(9):2394-2400.
26. Druker BJ, Imatinib as a paradigm of targeted therapies. Adv Cancer Res 2004, 91:1-30.
27. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y et al, Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361(10):947-957.
28. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M et al, Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344(11):783-792.
29. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C et al, Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004, 351(4):337-345.
30. Seynhaeve AL, Hoving S, Schipper D, Vermeulen CE, de Wiel-Ambagtsheer G, van Tiel ST, Eggermont AM, Ten Hagen TL, Tumor necrosis factor alpha mediates homogeneous distribution of liposomes in murine melanoma that contributes to a better tumor response. Cancer Res 2007, 67(19):9455-9462.
31. Frei E, 3rd, Canellos GP, Dose, a critical factor in cancer chemotherapy. Am J Med 1980, 69(4):585-594.
32. Muldoon LL, Soussain C, Jahnke K, Johanson C, Siegal T, Smith QR, Hall WA, Hynynen K, Senter PD, Peereboom DM et al, Chemotherapy delivery issues in central nervous system malignancy, a reality check. J Clin Oncol 2007, 25(16):2295-2305.
33. Balkwill F, Tumour necrosis factor and cancer. Nat Rev Cancer 2009, 9(5):361-371.